Trial ID or NCT#

NCT00466713

Status

NOT RECRUITING

Purpose

This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin-sensitizing medication will improve the heart's ability to metabolize glucose (sugar).

Official Title

Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Ronald Witteles, MD
Cardiologist, Heart failure cardiologist
Associate Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Michael B Fowler, MB
(650) 723-7846